{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-21-000041","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.561903+00:00","generated_at":"2026-06-29T22:45:50.702194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"10x Genomics Q2 revenue $115.8M (+170% YoY); settles Bio-Rad litigation","bullets":["Revenue $115.8M, up 170% YoY and 9% QoQ; net loss narrowed to $11.1M from $40.2M.","Gross margin 96% aided by $14.7M one-time royalty reversal from Bio-Rad settlement.","Launched Chromium X platform and began shipping Visium Spatial Gene Expression for FFPE.","Global settlement with Bio-Rad resolves all outstanding litigation; cross-license agreement.","Maintains FY2021 revenue guidance $480M-$500M, representing 61%-67% growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-21-000041","json":"https://secwatch.observer/filing/0001770787-21-000041.json","markdown":"https://secwatch.observer/filing/0001770787-21-000041.md","text":"https://secwatch.observer/filing/0001770787-21-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078721000041/0001770787-21-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078721000041/txg-20210804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:45:50.702194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}